A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute

Critical Reviews in Oncology/Hematology

Volumn 37, Issue 2, 2001, Pages 153-158

  Tirelli, Umberto ^a   Carbone, Antonino ^a   Monfardini, Silvio ^b   Zagonel, Vittorina ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b General Hospital   (Italy)

Author keywords

Elderly patients; Hodgkin's disease; non Hodgkin's lymphoma

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; VINCRISTINE SULFATE;

AGED; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; GRANULOCYTOPENIA; HODGKIN DISEASE; HUMAN; INFECTION; LYMPHOMA; MORTALITY; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; HUMANS; LYMPHOMA;

EID: 0035141550     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00103-7     Document Type: Review

References (10)

1. Non-Hodgkin's lymphoma in the elderly, 1. Pathologic features at presentation
2. Non-Hodgkin's lymphoma in 137 patients aged 70 years or older. A retrospective European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group Study
3. Non-Hodgkin's lymphomas in the elderly. Prospective studies with specifically devised chemotherapy regimens in 66 patients
4. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavourable non-Hodgkin's lymphoma
5. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group
6. Effects of G-CSF in patients with non-Hodgkin's lymphomas (NHL) older than 70 years
7. Cost-benefit of granuolocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
8. Hodgkin's disease in patients 70 years of age or more. A retrospective EORTC lymphoma group study
9. CH1VPP therapy for Hodgkin's disease: experience of 960 patients
10. Reduced delivery of systemic therapy to elderly patients with Hodgkin's disease: a contribution to poor outcome